Northwest Biotherapeutics (NWBO) Liabilities and Shareholders Equity (2010 - 2026)

Northwest Biotherapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $80.1 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 191.04% year-over-year to $80.1 million; the TTM figure through Mar 2026 stood at $221.5 million (up 98.16% YoY), while the FY2025 annual figure was $81.3 million, up 204.14% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $80.1 million, down from $81.3 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $81.3 million in Q4 2025, with the low at $26.7 million in Q4 2024.
• The 5-year median for Liabilities and Shareholders Equity is $29.5 million (2025), against an average of $35.5 million.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity decreased 22.0% in 2022, then surged 204.14% in 2025.
• Northwest Biotherapeutics' Liabilities and Shareholders Equity stood at $31.3 million in 2022, then declined by 11.04% to $27.9 million in 2023, then decreased by 4.08% to $26.7 million in 2024, then soared by 204.14% to $81.3 million in 2025, then slipped by 1.52% to $80.1 million in 2026.
• Business Quant data shows NWBO's Liabilities and Shareholders Equity at $80.1 million in Q1 2026, $81.3 million in Q4 2025, and $30.6 million in Q3 2025.